Current Report Filing (8-k)
June 10 2021 - 4:06PM
Edgar (US Regulatory)
0000861838
false
0000861838
2021-06-08
2021-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC
20549
__________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION
13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report (Date of earliest event reported):
June 8, 2021
Idera
Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
001-31918
(Commission File
Number)
|
04-3072298
(I.R.S. Employer
Identification No.)
|
505 Eagleview Blvd., Suite 212
|
|
|
Exton, Pennsylvania
|
|
19341
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (484) 348-1600
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each
exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
IDRA
|
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
At the 2021 Annual Meeting of Stockholders of Idera
Pharmaceuticals, Inc. (the “Company”) held on June 8, 2021 (the “2021 Annual Meeting”), a total of 28,293,742
shares were represented by conference call participation or by proxy, which represented a quorum. At the 2021 Annual Meeting, the stockholders
of the Company voted on (1) the election of two Class II directors for terms to expire at the Company’s 2024 annual meeting of stockholders,
(2) approval, on a non-binding basis, of the compensation of the Company’s named executive officers for 2020, and (3) the ratification
of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending
December 31, 2021. The voting results on these proposals were as follows:
Proposal 1. Elect two Class II directors for terms to expire at
the Company’s 2024 annual meeting of stockholders.
Nominee
|
|
Votes For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
James A. Geraghty
|
|
|
15,849,257
|
|
|
|
1,307,675
|
|
|
|
11,136,810
|
|
Maxine Gowen, Ph.D
|
|
|
16,888,682
|
|
|
|
268,250
|
|
|
|
11,136,810
|
|
Proposal 2. Approve, by non-binding vote, of the compensation of
the Company’s named executive officers for 2020.
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
16,462,462
|
|
|
|
593,632
|
|
|
|
100,838
|
|
|
|
11,136,810
|
|
Proposal 3. Ratify the selection of Ernst & Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
28,017,851
|
|
|
|
149,587
|
|
|
|
126,304
|
|
|
|
0
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDERA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Bryant D. Lim
|
|
|
Bryant D. Lim
|
|
|
Senior V.P., General Counsel
|
Dated: June 10, 2021
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024